Shares of Auris Medical Holding AG (NASDAQ:EARS) traded down 3.2% on Thursday . The stock traded as low as $3.95 and last traded at $3.96, with a volume of 96,772 shares changing hands. The stock had previously closed at $4.09.

Several analysts recently weighed in on the stock. Leerink Swann reiterated a “buy” rating on shares of Auris Medical Holding AG in a report on Thursday, May 12th. Jefferies Group dropped their target price on shares of Auris Medical Holding AG from $12.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 15th.

The company has a 50-day moving average of $3.71 and a 200-day moving average of $4.09. The firm’s market capitalization is $138.35 million.

Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.04. During the same quarter last year, the business posted ($0.28) EPS. Analysts forecast that Auris Medical Holding AG will post ($1.01) EPS for the current year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.